BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 28751539)

  • 1. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
    Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
    Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
    Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
    Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
    J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
    Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
    Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
    Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
    Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE
    Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
    Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.